AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions
UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...
Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme
The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS
Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...
Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...
Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval
China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...
Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...
Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study
China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...
China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval
On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...
Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval
China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...
Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China
The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...